Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research, Inc. | PRODUCT CODE: 1122284

Cover Image

PUBLISHER: Grand View Research, Inc. | PRODUCT CODE: 1122284

Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report By Production Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disorders), By Product, By Region, And Segment Forecasts, 2022 - 2030

PUBLISHED:
PAGES: 275 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Biosimilar Contract Manufacturing Market Growth & Trends:

The global biosimilar contract manufacturing market size is expected to reach USD 25.7 billion by 2030, registering a CAGR of 18.5% during the forecast period, according to a new report by Grand View Research, Inc. Growing demand for low-cost therapeutics and the increasing prevalence of diseases, such as cancer, autoimmune disorders, blood disorders, and other diseases are the major factors driving the industry. In recent years, the approvals for biosimilar drugs have increased. For instance, in August 2022, the U.S. FDA approved Coherus' drug Cimerli as an interchangeable biosimilar for Lucentis.

This biosimilar is used in treating ophthalmology conditions, such as Diabetic Macular Edema (DME), Macular Edema following Retinal Vein Occlusion (RVO), Neovascular (wet) Age-Related Macular Degeneration (AMD) Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularization (mCNV). A growing number of biosimilar approvals are expected to profit the industry post-pandemic. There has been a rise in the number of biologics losing patents. For instance, biologics, such as Humira, Eylea, Keytruda, Stelara, Revlimid, and Eliquis, are expected to lose patents by 2030. The growing number of biologics losing patents is expected to promote the demand for biosimilars, thus promoting industry growth.

A significant number of small- and medium-sized biopharmaceutical companies lack infrastructure for manufacturing biosimilars. Furthermore, big pharmaceutical companies try to focus on their core competencies, such as research and marketing, owing to which they outsource manufacturing services. Such factors are further expected to promote industry growth to a great extent. Cancer is one of the major causes of death worldwide. The estimates of Cancer Tomorrow state that cancer is expected to affect 30.2 million people by 2040. The rising burden of the disease and the high cost of drugs are expected to promote the demand for low-cost biosimilars. This is likely to improve the manufacturing of cancer biosimilar in the post-pandemic period.

Biosimilar Contract Manufacturing Market Report Highlights:

  • The mammalian production technology segment dominated the industry in 2021 as the majority of research activities are being carried out using mammalian cell lines
  • The recombinant non-glycosylated proteins segment accounted for the largest revenue share in 2021 owing to its effectiveness in treating diseases, such as cancer and diabetes
  • The chronic and autoimmune disorders segment held the largest share of the overall revenue in 2021
  • The growing burden of autoimmune diseases is one of the key factors driving the growth of this segment
  • Asia Pacific is expected to register the fastest CAGR over the forecast period due to the growing aging population and high prevalence of chronic & infectious diseases in the region, thus promoting the demand for cost-effective treatments
Product Code: GVR-4-68039-970-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Production Technology
    • 1.1.2. Application
    • 1.1.3. End-user
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Biosimilar Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Increasing disease prevalence
      • 3.3.1.2. Low cost of Biosimilar
      • 3.3.1.3. Growing R&D investments in Biosimilars
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. Quality Issues associated with Contract Manufacturing
      • 3.3.2.2. Limited outsourcing amongst well-established biopharmaceutical manufacturers
  • 3.4. Biosimilar Contract Manufacturing Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
    • 3.4.2. PESTEL Analysis
    • 3.4.3. Major Deals & Strategic Alliances Analysis
  • 3.5. Covid-19 Impact Analysis

Chapter 4. Biosimilar Contract Manufacturing Market: Product Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Biosimilar Contract Manufacturing Market Share, 2021 & 2030
    • 4.2.1. Recombinant Non-Glycosylated Proteins
      • 4.2.1.1. Recombinant Non-Glycosylated Proteins market estimates and forecast, 2018 to 2030 (USD Billion)
    • 4.2.2. Recombinant Glycosylated Proteins
      • 4.2.2.1. Recombinant Glycosylated Proteins market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Biosimilar Contract Manufacturing Market: Production Technology Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Biosimilar Contract Manufacturing Market Share, 2021 & 2030
    • 5.2.1. Mammalian
      • 5.2.1.1. Mammalian market estimates and forecast, 2018 to 2030 (USD Billion)
    • 5.2.2. Non-Mammalian
      • 5.2.2.1. Non-Mammalian market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 6. Biosimilar Contract Manufacturing Market: Application Estimates & Trend Analysis

  • 6.1. Definitions and Scope
  • 6.2. Biosimilar Contract Manufacturing Market Share, 2021 & 2030
    • 6.2.1. Oncology
      • 6.2.1.1. Oncology market estimates and forecast, 2018 to 2030 (USD Billion)
    • 6.2.2. Blood Disorders
      • 6.2.2.1. Blood Disorders market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 6.2.3. Growth Hormonal Deficiency
      • 6.2.3.1. Growth Hormonal Deficiency market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 6.2.4. Rheumatoid Arthritis
      • 6.2.4.1. Rheumatoid Arthritis market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 6.2.5. Chronic & Autoimmune Diseases
      • 6.2.5.1. Chronic & Autoimmune Diseases market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 6.2.6. Others
      • 6.2.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 7. Biosimilar Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional market share analysis, 2021 & 2030
  • 7.2. North America
    • 7.2.1. U.S.
      • 7.2.1.1. U.S. market estimates and forecasts, 2018 - 2030
    • 7.2.2. Canada
      • 7.2.2.1. Canada market estimates and forecasts, 2018 - 2030
  • 7.3. Europe
    • 7.3.1. U.K.
      • 7.3.1.1. U.K. market estimates and forecasts, 2018 - 2030
    • 7.3.2. Germany
      • 7.3.2.1. Germany market estimates and forecasts, 2018 - 2030
    • 7.3.3. France
      • 7.3.3.1. France market estimates and forecasts, 2018 - 2030
    • 7.3.4. Italy
      • 7.3.4.1. Italy market estimates and forecasts, 2018 - 2030
    • 7.3.5. Spain
      • 7.3.5.1. Spain market estimates and forecasts, 2018 - 2030
  • 7.4. Asia Pacific
    • 7.4.1. Japan
      • 7.4.1.1. Japan market estimates and forecasts, 2018 - 2030
    • 7.4.2. China
      • 7.4.2.1. China market estimates and forecasts, 2018 - 2030
    • 7.4.3. India
      • 7.4.3.1. India market estimates and forecasts, 2018 - 2030
    • 7.4.4. Australia
      • 7.4.4.1. Australia market estimates and forecasts, 2018 - 2030
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea market estimates and forecasts, 2018 - 2030
  • 7.5. Latin America
    • 7.5.1. Brazil
      • 7.5.1.1. Brazil market estimates and forecasts, 2018 - 2030
    • 7.5.2. Mexico
      • 7.5.2.1. Mexico market estimates and forecasts, 2018 - 2030
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina market estimates and forecasts, 2018 - 2030
  • 7.6. MEA
    • 7.6.1. South Africa
      • 7.6.1.1. South Africa market estimates and forecasts, 2018 - 2030
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Company Profiles
    • 8.1.1. Boehringer Ingelheim Biopharmaceuticals GmbH
      • 8.1.1.1. Company overview
      • 8.1.1.2. Product benchmarking
      • 8.1.1.3. Strategic initiatives
    • 8.1.2. Lonza
      • 8.1.2.1. Company overview
      • 8.1.2.2. Financial performance
      • 8.1.2.3. Product benchmarking
      • 8.1.2.4. Strategic initiatives
    • 8.1.3. Catalent Inc
      • 8.1.3.1. Company overview
      • 8.1.3.2. Financial performance
      • 8.1.3.3. Product benchmarking
      • 8.1.3.4. Strategic initiatives
    • 8.1.4. Biocon
      • 8.1.4.1. Company overview
      • 8.1.4.2. Financial performance
      • 8.1.4.3. Product benchmarking
      • 8.1.4.4. Strategic initiatives
    • 8.1.5. IQVIA Inc.
      • 8.1.5.1. Company overview
      • 8.1.5.2. Financial performance
      • 8.1.5.3. Product benchmarking
      • 8.1.5.4. Strategic initiatives
    • 8.1.6. AGC Biologics.
      • 8.1.6.1. Company overview
      • 8.1.6.2. Financial performance
      • 8.1.6.3. Product benchmarking
      • 8.1.6.4. Strategic initiatives
    • 8.1.7. Samsung Biologics.
      • 8.1.7.1. Company overview
      • 8.1.7.2. Financial performance
      • 8.1.7.3. Product benchmarking
      • 8.1.7.4. Strategic initiatives
    • 8.1.8. WuXi Biologics.
      • 8.1.8.1. Company overview
      • 8.1.8.2. Financial performance
      • 8.1.8.3. Product benchmarking
      • 8.1.8.4. Strategic initiatives
    • 8.1.9. Element Materials Technology
      • 8.1.9.1. Company overview
      • 8.1.9.2. Financial performance
      • 8.1.9.3. Product benchmarking
      • 8.1.9.4. Strategic initiatives
    • 8.1.10. Rentschler Biopharma SE
      • 8.1.10.1. Company overview
      • 8.1.10.2. Financial performance
      • 8.1.10.3. Product benchmarking
      • 8.1.10.4. Strategic initiatives
    • 8.1.11. Avid Bioservices, Inc.
      • 8.1.11.1. Company overview
      • 8.1.11.2. Financial performance
      • 8.1.11.3. Product benchmarking
      • 8.1.11.4. Strategic initiatives
    • 8.1.12. Alcami Corporation, Inc.
      • 8.1.12.1. Company overview
      • 8.1.12.2. Financial performance
      • 8.1.12.3. Product benchmarking
      • 8.1.12.4. Strategic initiatives
    • 8.1.13. FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
      • 8.1.13.1. Company overview
      • 8.1.13.2. Financial performance
      • 8.1.13.3. Product benchmarking
      • 8.1.13.4. Strategic initiatives
    • 8.1.14. Thermo Fisher Scientific Inc
      • 8.1.14.1. Company overview
      • 8.1.14.2. Financial performance
      • 8.1.14.3. Product benchmarking
      • 8.1.14.4. Strategic initiatives
    • 8.1.15. Almac Group
      • 8.1.15.1. Company overview
      • 8.1.15.2. Financial performance
      • 8.1.15.3. Product benchmarking
      • 8.1.15.4. Strategic initiatives
Product Code: GVR-4-68039-970-1

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 Biosimilar contract manufacturing market snapshot (2021)
  • Fig. 11 Biosimilar contract manufacturing market segmentation
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 Biosimilar contract manufacturing market product outlook: Segment dashboard
  • Fig. 18 Biosimilar contract manufacturing market: product movement analysis
  • Fig. 19 Recombinant Non-Glycosylated Proteins market, 2018 - 2030 (USD Billion)
  • Fig. 20 Recombinant Glycosylated Proteins market, 2018 - 2030 (USD Billion)
  • Fig. 21 Biosimilar contract manufacturing market production technology outlook: Segment dashboard
  • Fig. 22 Biosimilar contract manufacturing market: production technology movement analysis
  • Fig. 23 Mammalian market, 2018 - 2030 (USD Billion)
  • Fig. 24 Non-Mammalian market, 2018 - 2030 (USD Billion)
  • Fig. 25 Biosimilar contract manufacturing market application outlook: Segment dashboard
  • Fig. 26 Biosimilar contract manufacturing market: application movement analysis
  • Fig. 27 Oncology market, 2018 - 2030 (USD Billion)
  • Fig. 28 Blood Disorders market, 2018 - 2030 (USD Billion)
  • Fig. 29 Growth Hormone Deficiency market, 2018 - 2030 (USD Billion)
  • Fig. 30 Rheumatoid Arthritis market, 2018 - 2030 (USD Billion)
  • Fig. 31 Chronic and Autoimmune Diseases market, 2018 - 2030 (USD Billion)
  • Fig. 32 Others market, 2018 - 2030 (USD Billion)
  • Fig. 33 Regional market: Key takeaways
  • Fig. 34 Regional outlook, 2021 & 2030
  • Fig. 35 North America market, 2018 - 2030 (USD Billion)
  • Fig. 36 U.S. market, 2018 - 2030 (USD Billion)
  • Fig. 37 Canada market, 2018 - 2030 (USD Billion)
  • Fig. 38 Europe market, 2018 - 2030 (USD Billion)
  • Fig. 39 U.K. market, 2018 - 2030 (USD Billion)
  • Fig. 40 Germany market, 2018 - 2030 (USD Billion)
  • Fig. 41 France market, 2018 - 2030 (USD Billion)
  • Fig. 42 Italy market, 2018 - 2030 (USD Billion)
  • Fig. 43 Spain market, 2018 - 2030 (USD Billion)
  • Fig. 44 Asia Pacific market, 2018 - 2030 (USD Billion)
  • Fig. 45 China market, 2018 - 2030 (USD Billion)
  • Fig. 46 India market, 2018 - 2030 (USD Billion)
  • Fig. 47 Japan market, 2018 - 2030 (USD Billion)
  • Fig. 48 Australia market, 2018 - 2030 (USD Billion)
  • Fig. 49 South Korea market, 2018 - 2030 (USD Billion)
  • Fig. 50 Latin America market, 2018 - 2030 (USD Billion)
  • Fig. 51 Brazil market, 2018 - 2030 (USD Billion)
  • Fig. 52 Mexico market, 2018 - 2030 (USD Billion)
  • Fig. 53 Argentina market, 2018 - 2030 (USD Billion)
  • Fig. 54 MEA market, 2018 - 2030 (USD Billion)
  • Fig. 55 South Africa market, 2018 - 2030 (USD Billion)
  • Fig. 56 Saudi Arabia market, 2018 - 2030 (USD Billion)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!